Legal & General Group Plc lowered its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 20.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,835,793 shares of the medical equipment provider's stock after selling 462,702 shares during the quarter. Legal & General Group Plc owned approximately 0.81% of Hologic worth $132,342,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also modified their holdings of HOLX. General Partner Inc. purchased a new position in Hologic during the 4th quarter worth $26,000. Venturi Wealth Management LLC increased its stake in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Smithfield Trust Co lifted its position in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 400 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.
Hologic Stock Down 1.4 %
Hologic stock traded down $0.83 during midday trading on Wednesday, hitting $57.03. 697,625 shares of the company were exchanged, compared to its average volume of 1,918,488. The company's fifty day moving average price is $62.04 and its 200-day moving average price is $71.25. The company has a market cap of $12.80 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a fifty-two week low of $56.27 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.
Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on HOLX shares. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Argus lowered Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Evercore ISI cut their price target on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. William Blair reissued an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Finally, Raymond James restated an "outperform" rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $84.62.
Check Out Our Latest Research Report on Hologic
Hologic Company Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Articles
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
